Thioaptamer oligonucleotide ligands against endothelial E-selectin protein.




Market:­ Inflammatory diseases affect millions of people in the United States.  For example, 1.3 million Americans suffer from rheumatoid arthritis; 81 million Americans suffer from atherosclerosis or some other form of cardiovascular disease; and 25.8 million Americans suffer from diabetes.  Additionally, cancer is also an inflammatory disease.


Competitors and Current Problems: Currently, anti-inflammatory drugs (steroids and NSAIDs) do not specifically target local inflammation sites.  The ability to target drug delivery locally would improve the effectiveness of therapeutics while minimizing the drug exposure of normal tissues.


The Technology: Researchers have identified and isolated a nucleic acid aptamer that binds tightly to E-selectin.  E-selectin is expressed by endothelial cells exclusively in response to inflammation.  The aptamer binds to E-selectin with high affinity and specificity.  Thus, the aptamer can be used to target delivery of therapeutics and imaging contrast agents for the treatment of inflammatory diseases such as rheumatoid arthritis, atherosclerosis, diabetes, and cancer. The E-selectin aptamer itself also shows promise as an  anti-inflamatory agent itself.


Keywords: E-selectin; inflammation, rheumatoid arthritis, atherosclerosis, diabetes, cancer; contrast agents


UTHealth Ref. No.: 2010-0007

Inventors: Gorenstein et al.

Patent Status: Issued U.S. Patent 8,658,614

License Available: world-wide; exclusive or non-exclusive


To obtain further information about this technology, please contact:

Office of Technology Management, 7000 Fannin, Suite 720, Houston, TX, 77030

Phone: (713) 500-3369 Fax: (713) 500-0331



Patent Information:

The preceding is intended to be a non-confidential and limited description of a novel technology created at the University of Texas Health Science Center at Houston (UTHealth). This promotional material is not comprehensive in scope and should not replace company’s diligence in a thorough evaluation of the technology. Please contact the Office of Technology Management for more information regarding this technology.
For Information, Contact:
Ayesha Siddiqi
Technology Licensing Associate
University of Texas Health Science Center At Houston
© 2022. All Rights Reserved. Powered by Inteum